Adaptimmune revives ovarian cancer trial
T-cell trial will include controversial chemo agent fludarabine.
X
Adaptimmune revives ovarian cancer trial
https://pharmaphorum.com/news/adaptimmune-revives-ovarian-cancer-trial/
T-cell
Adaptimmune progresses T-cell therapy trial
Biotech says “robust” clinical response in early stage trial.
Promise for combination approach to cancer
As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.
FDA calls for hold on Adaptimmune T-cell trial
Regulator asks for information on trial design.
Juno restarts CAR-T trial after deaths
Biotech continues blood cancer trial after deaths.
